There are incredible data for sodium-glucose co-transporter 2 (SGLT2) inhibitors, and this is a great class of medicines that is vastly underutilized, stated Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School.
There are incredible data for sodium-glucose co-transporter 2 (SGLT2) inhibitors, and this is a great class of medicines that is vastly underutilized. With the positive trials we have, it's time to prescribe drugs from this class, stated Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School.
Bhatt's presentation "Benefits of SGLT2-1/2 Inhibition on Heart Failure, Ischemic, and Kidney Endpoints," will be available on-demand during ESC Congress 2021, this year's virtual meeting of the European Society of Cardiology.
Transcript
What can be done for more providers to prescribe SGLT2 inhibitors, and what can payers do?
We're sort of at the stage with SGLT2 inhibitors as a class where we were with statins maybe a decade ago—where there were enough positive trials that if you're sitting on the sidelines being a skeptic, well, then you're just one of those science deniers. I mean, the data for SGLT2 inhibitors are incredibly good.
Yes, there's the occasional patient that might get DKA [diabetic ketoacidosis]. Yes, you've got to be on the lookout for those sort of things, especially in patients with diabetes vs no diabetes, especially if they're on insulin, etc. Like every drug, you have to know how to use it.
Putting aside that typical practicing medicine type of common sense, this is a great class of medicines. It's vastly underutilized. Yes, some of that has to do with cost issues, but some of it's also just lack of knowledge of the data by physicians, some of it’s the typical clinical inertia that kicks in, some of it’s, “Oh, I need to see another trial before I get on board,” sort of thing.
But at this point, there are enough positive trials. It's time to find the appropriate patients and prescribe drugs from this class. And I'd say whichever one’s on the formulary, use that one. Don't worry so much about some of the issues even we discussed about which SGLT2 inhibitor is better. Certainly any is better than none.
So I would say, the implementation science is really big. And in terms of what third-party payers can do, some of the barrier to the uptake of SGLT2 inhibitors has just been the high co-pays that are quite common. And I think in patients with heart failure, I believe across the full range of ejection fraction, we proved in SOLOIST and SCORED that starting sotagliflozin was safe, with careful monitoring and clinical judgement and that sort of thing. But it was safe and was highly effective with large absolute risk reductions.
I'm more interested in the clinical aspects, but with large economic consequences, too, by preventing a lot of hospitalizations for heart failure, including that 30-day early window, get penalized if it happens in terms of hospital penalties and so forth. So I think it makes a lot of sense beyond just to do the right thing for the patient, just for the hospital and health care system to prevent those avoidable admissions and reduce health care costs to an extent by doing that. But that only works if the third-party payer is going to allow the SGLT2 inhibitor to be started in the hospital.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More